Protecting future antimalarials from the trap of resistance: Lessons from artemisinin-based combination therapy (ACT) failures.

ABSTRACT: Having faced increased clinical treatment failures with dihydroartemisinin-piperaquine (DHA-PPQ), Cambodia swapped the first line artemisinin-based combination therapy (ACT) from DHA-PPQ to artesunate-mefloquine given that parasites resistant to piperaquine are susceptible to mefloquine. However, triple mutants have now emerged, suggesting that drug rotations may not be adequate to keep resistance at bay. There is, therefore, an urgent need for alternative treatment strategies to tackle resistance and prevent its spread. A proper understanding of all contributors to artemisinin resistance may help us identify novel strategies to keep artemisinins effective until new drugs become available for their replacement. This review highlights the role of the key players in artemisinin resistance, t

SUBMITTER: Erhunse N 

PROVIDER: S-EPMC8572664 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature